Development of Bell’s Palsy After Treatment With Ipilimumab and Nivolumab for Metastatic Melanoma: A Case Report

We report a case of Bell’s palsy in a 45-year-old male patient who received 1 dose of both ipilimumab and nivolumab for the treatment of metastatic melanoma. After the resolution of symptoms, ipilimumab was permanently discontinued and single-agent nivolumab administered. The patient has remained free of neurological symptoms. This case suggests that Bell’s palsy is an irAE induced by ipilimumab.
Source: Journal of Immunotherapy - Category: Allergy & Immunology Tags: Case Reports Source Type: research